Table 2.
Clinical parameters before and after treatment with praziquantel (dose 40 mg/kg)
| Before praziquantel n (%) | After praziquantel n (%) | Odds ratio (CI 95%) | P value | |
|---|---|---|---|---|
| Macroscopic hematuria | 10 (14.2%) | 3 (4.3%) | 3.7 (0.9–21.8) | 0.04 |
| ≤ 10y (N = 39) | 5/39 (12.8%) | 3/39 (7.7%) | 1.76 (0.3–12.1) | 0.46 |
| > 10y (N = 31) | 5/31 (16.1%) | 0 | – | – |
| Microscopic hematuria | 62 (88.5%) | 22 (31.4%) | 16.9 (6.5–46.9) | < 0.01 |
| ≤ 10y (N = 39) | 35/39 (89.7%) | 15/39 (38.4%) | 14 (3.7–62.7) | < 0.01 |
| > 10y (N = 31) | 27/31 (87.1%) | 7/31 (22.6%) | 23.1 (5.2–115.5) | < 0.01 |
| + | 15 (21.4%) | 4 (5.7%) | 4.5 (1.3–19.5) | < 0.01 |
| ++ | 10 (14.3%) | 5 (7.1%) | 2.2 (0.6–8.5) | 0.17 |
| +++ | 37 (52.8%) | 13 (18.6%) | 4.9 (2.2–11.5) | < 0.01 |
| Proteinuria | 43 (61.4%) | 21 (30%) | 3.7 (1.7–7.9) | < 0.01 |
| ≤ 10y (N = 39) | 21/39 (53.8%) | 15/39 (38.4%) | 1.9 (0.7–5.1) | 0.17 |
| > 10y (N = 31) | 22/31 (70.9%) | 6/31 (19.3%) | 10.2 (2.8–39.9) | < 0.01 |
| + | 22 (31.4%) | 11 (15.7%) | 2.5 (1.0–6.2) | 0.03 |
| ++ | 9 (12.8%) | 7 (10%) | 1.3 (0.4–4.5) | 0.59 |
| +++ | 12 (17.1%) | 3 (4.3%) | 4.6 (1.2–26.5) | 0.01 |
| Schistosoma haematobium eggs | 70 (100%) | 18 (25.7%) | 199.3 (25.8–541.6) | < 0.01 |
| ≤ 10y (N = 39) | 39/39 (100%) | 12/39 (30.7%) | 85.5 (10.5–697.4) | < 0.01 |
| > 10y (N = 31) | 31/31 (100%) | 6/31 (19.3%) | 125.0 (14.1–108.6) | < 0.01 |
| Median ultrasound score | 5,50 | 1.40 | – | < 0.01 |
| ≤ 10y (N = 39) | 5,33 (IQR 2–8) | 1,72 (IQR 0–2) | < 0.01 | |
| > 10y (N = 31) | 5,71 (IQR 2–9) | 1,00 (IQR 0–1) | < 0.01 | |
| Bladder | 3,34 (IQR 2–5) | 0,56 (IQR 0–1) | < 0.01 | |
| Upper urinary tract | 2,16 (IQR 0–4) | 0,79 (IQR 0–0) | < 0.01 |
CI = confidence interval; IQR = interquartilic range.